BiotaSpin (Innovation Incubator 4.0)

Urolithin A is a postbiotic metabolite produced by the human gut microbiota, for which we were the first to demonstrate anti-inflammatory activity on the skin after topical administration of the compound. We are currently synthesizing urolithin A on a semi-technical scale and developing a semi-liquid formulation under an NCBiR grant. So far, in vitro and ex vivo studies on human neutrophils, macrophages and mouse macrophages models have been performed indicating strong structure-dependent anti-inflammatory properties of urolithin A.

Preclinical studies indicated the possibility of using ointment containing urolithin A in topical therapy of skin inflammation, for which hydrocortisone or other steroids are currently used. The subject of commercialization has intellectual property rights protection - application in the Polish Patent Office. Application date 29.11.2019, application no: P-427944, which entered the international phase on 29.11.2019 (PCT/IB2019/060337).